IL6R and COVID-19: We believe risk stratification to be of paramount importance for COVID-19 patients, as patients with the highest values may benefit most from anti-viral or anti-inflammatory therapies such as steroids, interleukin-6 receptor antagonists, or anti-JAK molecules.